NCT02527564View on ClinicalTrials.gov

Efficacy of Suvorexant to Treat Insomnia Related to Bipolar Disorder

PHASE4CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

March 1, 2021

Study Completion Date

March 1, 2021

Conditions
InsomniaBipolar Disorder
Interventions
DRUG

Suvorexant

DRUG

Placebo

Trial Locations (1)

94305

Stanford University, Stanford

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Stanford University

OTHER

NCT02527564 - Efficacy of Suvorexant to Treat Insomnia Related to Bipolar Disorder | Biotech Hunter | Biotech Hunter